Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395972 | 0.97 | CACNA1H (0.69) | CACNA1HALDH1A1LMNAHTTKMT2A | |
| SCHEMBL399195 | 0.97 | CACNA1H (0.69) | CACNA1HALDH1A1LMNAHTTKMT2A | |
| SCHEMBL398997 | 0.92 | ALDH1A1 (0.72) | CACNA1HALDH1A1LMNAHTTKMT2A | |
| SCHEMBL396082 | 0.89 | ALDH1A1 (0.70) | CACNA1HALDH1A1LMNAHTTKMT2A | |
| SCHEMBL15746822 | 0.89 | ALDH1A1 (0.70) | CACNA1HALDH1A1LMNAHTTKMT2A | |
| SCHEMBL397752 | 0.89 | ALDH1A1 (0.66) | CACNA1HALDH1A1LMNAHTTKMT2A | |
| SCHEMBL397289 | 0.88 | ALDH1A1 (0.68) | ALDH1A1LMNAHTTKMT2AL3MBTL1 | |
| SCHEMBL399539 | 0.87 | CACNA1H (0.75) | CACNA1HALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL396044 | 0.83 | CACNA1H (0.74) | CACNA1HALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL395605 | 0.83 | CACNA1H (0.74) | CACNA1HALDH1A1LMNAHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382191-B1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE BAHAMAS LTD (BS) | 2014-11-12 | — | — | EP | claimed |
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-08-15 | — | — | US | claimed |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | claimed |
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PREC MEDICINES INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2021-02-11 | — | — | US | disclosed |
| WO-2018118101-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-2382191-B1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE BAHAMAS LTD (BS) | 2014-11-12 | — | — | EP | disclosed |
| US-8741899-B2 | (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8101614-B2 | Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | CACNA1H 13/4885ALDH1A1 1038/4885LMNA 868/4885 |
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | APP, CACNA1G, CACNA1B | CACNA1H 11/4885ALDH1A1 2709/4885LMNA 526/4885 |
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CACNA1G, CACNA1H, CACNA1I | CACNA1H 2/4885ALDH1A1 3980/4885LMNA 1252/4885 |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | CACNA1H 13/4885ALDH1A1 1038/4885LMNA 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.